March Biosciences
Developer of cell-based therapies designed for the treatment of hematological cancers. The company integrates biologically informed target selection with simplified, gene-editing-free CAR-T engineerin...
Valuation
$47M
Latest known
Share Price
N/A
Total Raised
$33.2M
Last Round
N/A